ePrints

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5

Lookup NU author(s): Emeritus Professor Philip Home

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

AimsTo investigate the efficacy and tolerability of albiglutide, a weekly glucagon-like peptide-1 receptor agonist, when added to metformin and glimepiride in a triple therapy regimen in people with type 2 diabetes mellitus.MethodsThis was a 156-week, randomized, double-blind, parallel-group, multicentre study. In the present paper we describe the primary results, namely those at 52weeks. Adult participants (n=685) were randomly assigned to albiglutide (30mg/week), pioglitazone (30mg/day) or placebo. If needed, blinded uptitration of albiglutide (to 50mg/week) and pioglitazone (to 45mg/day) was allowed. The participant's current dose of metformin (>1500mg/day) was maintained throughout. The glimepiride dose (4mg/day), standardized before randomization, could be decreased if persistent hypoglycaemia occurred.ResultsThe week 52 model-adjusted difference in change of glycated haemoglobin (primary endpoint) for albiglutide versus placebo was -0.87 [95% confidence interval (CI) -1.07, -0.68]%-units (p<0.001), and for albiglutide versus pioglitazone it was 0.25 (95% CI 0.10, 0.40)%-units; therefore, not non-inferior. In the albiglutide group only, fasting plasma glucose reduced rapidly in the first 2weeks. Confirmed hypoglycaemia occurred in 14% of participants on albiglutide, 25% on pioglitazone and 14% on placebo. The mean ( standard error) weight change was -0.42 (+/- 0.2)kg with albiglutide, +4.4 (+/- 0.2)kg (p<0.001) with pioglitazone, and -0.40 (+/- 0.4)kg with placebo and serious adverse events occurred in 6.3, 9.0 and 6.1% of participants in the respective groups. Injection site reactions occurred in 13% of participants on albiglutide and resulted in treatment discontinuation for four participants (1.4%).ConclusionsAlbiglutide, as part of triple therapy, provided effective glucose-lowering and was generally well tolerated.

Publication metadata

Author(s): Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, Carr MC

Publication type: Article

Publication status: Published

Journal: Diabetes, Obesity and Metabolism

Year: 2015

Volume: 17

Issue: 2

Pages: 179-187

Print publication date: 01/02/2015

Online publication date: 10/12/2014

ISSN (print): 1462-8902

ISSN (electronic): 1463-1326

Publisher: Wiley-Blackwell Publishing

URL: http://dx.doi.org/10.1111/dom.12414

DOI: 10.1111/dom.12414

Altmetrics

Share